Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus propofol for laryngeal mask airway insertion in breast cancer surgery
ACTRN12625000675426Phase 4Not yet recruiting
- Sponsor
- University Hospital Center Sestre milosrdnice
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and propofol in breast cancer (2 arms), sponsored by University Hospital Center Sestre milosrdnice. Primary endpoint: Difference in the graded scale for assessing conditions for LMA insertion. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
remimazolampropofol
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12625000675426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000675426.